Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma

Status Terminated

Clinical Trial Summary

Current therapies for advanced Mesothelioma provide limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of advanced Mesothelioma. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on patients with advanced Mesothelioma.

Clinical Trial Description

Advanced Mesothelioma patients receive gradually escalating doses of intravenous Antineoplaston therapy (Atengenal + Astugenal) until the maximum tolerated dose is reached. Treatment continues up to 12 months in the absence of disease progression or unacceptable toxicity. OBJECTIVES: - To determine the efficacy of Antineoplaston therapy in patients with advanced Mesothelioma, as measured by an objective response to therapy (complete response, partial response or stable disease). - To determine the safety and tolerance of Antineoplaston therapy in patients with advanced Mesothelioma. - To determine objective response, tumor size is measured utilizing physical examination and radiologic studies, performed every 8 weeks for the first two years, every 3 months for the third and fourth years, every 6 months for the 5th and sixth years, and annually thereafter. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00003508
Study type	Interventional
Source	Burzynski Research Institute
Contact
Status	Terminated
Phase	Phase 2
Start date	March 8, 1996
Completion date	April 26, 2005

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06057935` - A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma	Phase 2
Completed	`NCT00075699` - Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma	Phase 3
Completed	`NCT00821860` - Video-Assisted Surgery or Talc Pleurodesis in Treating Patients With Malignant Mesothelioma	Phase 3
Completed	`NCT00004033` - Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma	Phase 2
Active, not recruiting	`NCT03678350` - Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery	Phase 1
Recruiting	`NCT02580747` - Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso	Phase 1
Completed	`NCT00398138` - Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma	Phase 1
Completed	`NCT00019825` - Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura	Phase 1
Terminated	`NCT00898547` - Biomarkers of Angiogenesis and Disease in Patients With Unresectable Malignant Mesothelioma Treated on Clinical Trial CALGB-30107
Active, not recruiting	`NCT00030459` - Palliative Therapy With or Without Chemotherapy in Treating Patients With Malignant Mesothelioma	Phase 2
Completed	`NCT00004183` - Capecitabine in Treating Patients With Malignant Mesothelioma	Phase 2
Completed	`NCT00004254` - Raltitrexed in Treating Patients With Malignant Mesothelioma That Cannot Be Surgically Removed	Phase 2
Completed	`NCT00005636` - Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery	Phase 3
Completed	`NCT00004920` - Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the Pleura	Phase 3
Completed	`NCT00334594` - Pemetrexed Disodium and Cisplatin Followed by Surgery With or Without Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma	Phase 2
Completed	`NCT01291420` - Dendritic Cell Vaccination for Patients With Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT03852823` - Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours	Phase 1
Active, not recruiting	`NCT01649024` - A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma	Phase 2
Completed	`NCT00513877` - Bortezomib in Treating Patients With Malignant Pleural Mesothelioma	Phase 2
Completed	`NCT00372840` - Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer	N/A